Read + Share
Beca JM, Walsh S, Raza K, Hubay S, et al. Cost-effectiveness analysis of first-line treatment with crizotinib in
ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. BMC Cancer 2021;21:1162.
PMID: 34715804
|
 |
|
Beca JM, Walsh S, Raza K, Hubay S, et al. Cost-effectiveness analysis of first-line treatment with crizotinib in
ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. BMC Cancer 2021;21:1162.
PMID: 34715804
|
|
|
|